Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | AOC2 | O75106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711525 | 1.00 | AOC3 (0.44) | AOC3KCNH2CYP11B1CYP11B2AOC2 | |
| SCHEMBL4902112 | 0.72 | CYP11B2 (0.40) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4901357 | 0.72 | CYP11B2 (0.38) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4902105 | 0.72 | CYP11B2 (0.40) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4901353 | 0.72 | CYP11B2 (0.38) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4903299 | 0.71 | CCR5 (0.48) | — | |
| SCHEMBL8258510 | 0.71 | CCR5 (0.38) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL8255904 | 0.70 | CYP11B2 (0.36) | AOC3KCNH2CYP11B1CYP11B2 | |
| SCHEMBL4011538 | 0.70 | CCR5 (0.42) | AOC3KCNH2CYP11B2 | |
| SCHEMBL6167230 | 0.70 | CCR5 (0.42) | AOC3KCNH2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | claimed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | AOC3 145/4885KCNH2 78/4885CYP11B1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.